Let me tell you a story. A global life sciences company – let’s call it Biospec International – was looking to recruit a lead scientist to help develop its pioneering treatment in matrix-assisted laser desorption/ionisation (MALDI). MALDI has significant implications for studying and treating diseases involving tissue-specific molecular changes. Key applications include cancer, neurodegenerative and infectious diseases, cardiovascular and metabolic disorders.
The number of people working in this highly specialised area of mass spectrometry globally is limited, and Biospec was fortunate to receive an application from Dr Carl Voss, who seemed to fit the bill perfectly. Dr Voss’s CV was impeccable – a PhD from an Ivy League university, a list of high-impact publications, and glowing references from industry leaders. More importantly, it was highly relevant to the kind of work the company was doing. His LinkedIn profile was polished, his cover letter compelling, and his initial video interview flawless. The hiring team was highly impressed and was delighted when he accepted the job.
The only problem for the company was that Dr. Voss didn’t exist – at least, not in the way he presented himself. His PhD was fabricated by AI, complete with a counterfeit university transcript. His publications were all AI-generated papers, uploaded to preprint servers with fake author lists. His references? Paid accomplices or AI-generated voice clones. His interview performance? Scripted by ChatGPT, with real-time AI assistance feeding him answers through an earpiece. For months in his new role, Dr Voss performed well, until the company discovered his research was unreproducible, his credentials were fraudulent and his work was dangerously flawed. By then, millions of dollars in R&D funding had been wasted, clinical trials compromised, and the company’s reputation damaged.
The above scenario is fictional and couldn’t possibly happen in real life because companies of the type described do extraordinary due diligence to ensure that the people they recruit are honest and credible. Or could it? The same claims were made by the aviation industry, which allowed Frank Abagnale – played by Leonardo DiCaprio in the film Catch Me If You Can – to bluff his way into the cockpit of a passenger airliner. AI and modern communication tools have made it easier than ever for scammers to infiltrate high-stakes industries like medical technology, biotech, and life sciences.
The Rise of Fake Research
Over the past decade, fraudulent operations that mass-produce fake research have industrialised the sale of bogus academic papers. These so-called “paper mills” profit by flooding scientific literature with fabricated studies, undermining trust in research used by doctors, engineers, and policymakers. To date, more than 55,000 fake academic papers have been withdrawn, but experts estimate that hundreds of thousands more fraudulent studies remain undetected. Fake research slows legitimate scientific progress, particularly in critical fields like medicine and cancer research. When fraudulent papers go unnoticed, they mislead researchers who waste time analysing fabricated data. Even when identified, journals often delay retractions, allowing flawed studies to persist in academic databases.
Many life science companies believe that their greatest protection against fraud is the highly specialist nature of the work they do, which makes it next to impossible to fake. But are they being dangerously complacent? A growing number of people within the sector fear that, similar to what happened in the financial service industry almost two decades ago, the very complexity of the work actually makes it easier for scammers to go undetected. The 2008 financial crash happened because securitised assets and other financial instruments, used to underwrite the global mortgage market, became so complicated that they were not understood by even the world’s most brilliant economists.
